The price increase stems from optimism over a melanoma vaccine developed with Merck, with full trial data due October 24. Gains were also driven by the company rejoining the Nasdaq 100, a move that forces index funds to purchase shares to maintain their holdings.
Tuesday, October 20, 2026
Story
Moderna Tops S&P 500 for 2026 With 663% Return
US Markets9 days ago
The biotechnology company's share price jumped 14% on Friday to close at $225. This rally extends Moderna's run as the best performing stock in the S&P 500 for 2026, with year to date returns now reaching 663%, surpassing the growth of most semiconductor stocks in the index.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.